Segment Information (Tables)

12 Months Ended

Dec. 31, 2022

Segment Reporting [Abstract]

Schedule of Net Sales and Segment Contribution for Each Reportable Segment

Net sales and segment contribution for each reportable segment for the year ended December 31, 2022 were as follows (in thousands):

	Wound & Surgical		Regenerative Medicine		Corporate & Other		Consolidated
Net sales	$	264,906	$	—	$	2,935	$	267,841
Cost of sales	44,462		—		3,854		48,316
Selling, general and administrative expense	145,887		—		62,902		208,789
Research and development expense	7,836		14,993		—		22,829
Amortization of intangible assets	—		—		701		701
Segment contribution	$	66,721	$	(14,993)
Investigation, restatement and related expense							12,177
Operating loss							$	(24,971)
Supplemental information
Depreciation expense	$	1,791	$	165	$	1,389	$	3,345
Share-based compensation	$	6,513	$	1,158	$	4,995	$	12,666

Net sales and segment contribution for each reportable segment for the year ended December 31, 2021 were as follows (in thousands):

	Wound & Surgical		Regenerative Medicine		Corporate & Other		Consolidated
Net sales	$	238,940	$	16,596	$	3,079	$	258,615
Cost of sales	35,204		3,655		4,424		43,283
Selling, general and administrative expense	123,583		12,910		61,866		198,359
Research and development expense	5,864		11,480		—		17,344
Amortization of intangible assets	—		—		820		820
Segment contribution	$	74,289	$	(11,449)
Investigation, restatement and related expense							3,791
Impairment of intangible assets							53
Operating loss							$	(5,035)
Supplemental information
Depreciation expense	$	1,644	$	246	$	2,473	$	4,363
Share-based compensation	$	5,158	$	1,461	$	8,138	$	14,757

Net sales and segment contribution for each reportable segment for the year ended December 31, 2020 were as follows (in thousands):

	Wound & Surgical		Regenerative Medicine		Corporate & Other		Consolidated
Net sales	$	213,489	$	32,362	$	2,383	$	248,234
Cost of sales	30,185		5,856		3,289		39,330
Selling, general and administrative expense	103,039		17,546		60,437		181,022
Research and development expense	3,979		7,736		—		11,715
Amortization of intangible assets	—		—		1,073		1,073
Segment contribution	$	76,286	$	1,224
Investigation, restatement and related expense							59,465
Impairment of intangibles							1,027
Operating loss							$	(45,398)
Supplemental information
Depreciation expense	$	1,755	$	451	$	3,576	$	5,782
Share-based compensation	$	4,373	$	1,256	$	9,728	$	15,357